Researchers have identified YAP and TAZ as crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis, ...

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

(NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant Therapeutics announced it has ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...